Inflammatory Breast Cancer: What We Know and What We Need to Learn
Hideko Yamauchi,Wendy A. Woodward,Vicente Valero,Ricardo H. Alvarez,Anthony Lucci,Thomas A. Buchholz,Takayuki Iwamoto,Savitri Krishnamurthy,Wei Tse Yang,James M. Reuben,Gabriel N. Hortobagyi,Naoto T. Ueno +11 more
Reads0
Chats0
TLDR
Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography-computed tomography, have improved the diagnosis and staging of inflammatory breast cancer, but the overall 5-year survival rate for patients with IBC remains very low.Abstract:
Purpose. We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease. Design. We performed a comprehensive review of the English-language literature on IBC through computerized literature searches. Results. Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography–computed tomography, have improved the diagnosis and staging of IBC. There are currentlynoestablishedmolecularcriteriafordistinguishing IBC from noninflammatory breast cancer. Such criteread more
Citations
More filters
Journal ArticleDOI
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Fatima Cardoso,Ana Costa,Larry Norton,Elżbieta Senkus,Matti Aapro,Fabrice Andre,Carlos H. Barrios,Jonas Bergh,Laura Biganzoli,Kimberly L. Blackwell,Maria João Cardoso,Tanja Cufer,N.S. El Saghir,Lesley Fallowfield,D. Fenech,Prudence A. Francis,Karen A. Gelmon,Sharon H. Giordano,Joseph Gligorov,A. Goldhirsch,Nadia Harbeck,Nehmat Houssami,Clifford A. Hudis,Bella Kaufman,Ian E. Krop,Stella Kyriakides,U. N. Lin,Musa Mayer,S. D. Merjaver,E. B. Nordström,Olivia Pagani,A.H. Partridge,Frédérique Penault-Llorca,Martine Piccart,Hope S. Rugo,George W. Sledge,Christoph Thomssen,L.J. van 't Veer,Daniel A. Vorobiof,Conny Vrieling,N. West,Bo Xu,Eric P. Winer +42 more
TL;DR: Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease, although the range is wide, and survival may be longer for patients treated in specialized institutions and within each country.
Journal ArticleDOI
Management of locally advanced breast cancer—perspectives and future directions
TL;DR: The authors discuss the current state of the art and possible future treatment strategies for patients with locally advanced breast cancer.
Journal ArticleDOI
Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database
Natasha M. Rueth,Heather Lin,Isabelle Bedrosian,Simona F. Shaitelman,Naoto T. Ueno,Yu Shen,Gildy Babiera +6 more
TL;DR: Underutilization of trimodality therapy negatively impacted survival for patients with inflammatory breast cancer and specific barriers to care are identified to improve treatment delivery and potentially improve patient outcomes.
Journal ArticleDOI
Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells
Evan N. Cohen,Hui Gao,Simone Anfossi,Michal Mego,Neelima Reddy,Bisrat G. Debeb,Antonio Giordano,S Tin,Qiong Wu,Raul J. Garza,Massimo Cristofanilli,Sendurai A. Mani,Denise Croix,Naoto T. Ueno,Wendy A. Woodward,Rajyalakshmi Luthra,Savitri Krishnamurthy,James M. Reuben +17 more
TL;DR: It is hypothesized that soluble factors secreted by activated immune cells can induce an EMT in IBC and thus promote metastasis and highlighted these factors as potential target mediators of immune-IBC interaction.
Journal ArticleDOI
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.
Naoto T. Ueno,Jose Rodrigo Espinosa Fernandez,Massimo Cristofanilli,Beth Overmoyer,Daniel Rea,Fedor Berdichevski,Mohamad El-Shinawi,Jennifer R. Bellon,Huong T. Le-Petross,Anthony Lucci,Gildy Babiera,Sarah M. DeSnyder,Mediget Teshome,Edward F. Chang,Bora Lim,Savitri Krishnamurthy,Michael C. Stauder,Simrit Parmar,Mona Mostafa Mohamed,Angela Alexander,Vicente Valero,Wendy A. Woodward +21 more
TL;DR: National and international experts in inflammatory breast cancer from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program at The University of Texas MD Anderson Cancer Center in Houston Texas to reach a consensus on the clinical management of patients with IBC.
References
More filters
Journal ArticleDOI
Rho GTPases and the Actin Cytoskeleton
TL;DR: Members of the Rho family of small guanosine triphosphatases have emerged as key regulators of the actin cytoskeleton, and through their interaction with multiple target proteins, they ensure coordinated control of other cellular activities such as gene transcription and adhesion.
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Book ChapterDOI
RHO Gtpases and the Actin Cytoskeleton
Hai Li,Zhenbiao Yang +1 more
TL;DR: Emerging evidence suggests that Rop also regulates actin organization and thus plays a crucial role in the control of cell morphogenesis in plants.
Journal ArticleDOI
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni,Wolfgang Eiermann,Vladimir Semiglazov,Alexey Manikhas,Ana Lluch,S. Tjulandin,Milvia Zambetti,Federico Vazquez,Mikhail Byakhow,Mikhail Lichinitser,Miguel Angel Climent,Eva Ciruelos,Belén Ojeda,Mauro Mansutti,Bozhok Aa,Roberta Baronio,A. Feyereislova,Claire Barton,Pinuccia Valagussa,José Baselga +19 more
TL;DR: The addition of neoadjuvant and adjuvant trastuzumab to neoadvuvant chemotherapy should be considered for women with HER2-positive locally advanced or inflammatory breast cancer to improve event-free survival, survival, and clinical and pathological tumour responses.
Journal ArticleDOI
Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging.
Yong Guo,You Quan Cai,Zu Long Cai,Yuan Gui Gao,Ning Yu An,Lin Ma,Srikanth Mahankali,Srikanth Mahankali,Jia-Hong Gao +8 more
TL;DR: To evaluate the value of diffusion‐weighted imaging (DWI) in distinguishing between benign and malignant breast lesions, a large number of patients were surveyed with and without breast cancer.